Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement

Bone and Joint Research

Volumn 3, Issue 5, 2014, Pages 146-149

  Jameson, S S ^a   Baker, P N ^a   Deehan, D J ^a,b   Port, A ^a   Reed, M R ^a,c  

^a SOUTH TEES HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NORTHUMBRIA HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Hip replacement; Knee replacement; NICE; Prophylaxis; Venous thromboembolism

Indexed keywords

EID: 84984887330     PISSN: None     EISSN: 20463758     Source Type: Journal    
DOI: 10.1302/2046-3758.35.2000225     Document Type: Article

References (42)

1. McMinn DJ, Snell KI, Daniel J, et al. Mortality and implant revision rates of hip arthroplasty in patients with osteoarthritis: registry based cohort study. BMJ 2012;344:3319.
2. No authors listed. National Joint Registry for England and Wales: 8th Annual Report, 2011. http://www.njrcentre.org.uk/NjrCentre/LinkClick.aspx?fileticket=1TQ%2bEiNejm0%3d&tabid=86&mid=523 (date last accessed 30 October 2013).
3. No authors listed. National Institute for Health and Clinical Excellence: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital http://www.nice.org.uk/nicemedia/live/12695/47920/47920.pdf (date last accessed 17 April 2014).
4. No authors listed. Surveillance of Surgical Site Infections in NHS Hospitals in England: Health Protection Agency. 2012. http://www.hpa.org.uk (date last accessed 17 April 2014).
5. Malviya A, Martin K, Harper I, et al. Enhanced recovery program for hip and knee replacement reduces death rate. Acta Orthop 2011;82:577-581.
6. No authors listed. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. The German Hip Arthroplasty Trial (GHAT) Group. Arch Orthop Trauma Surg 1992;111:110-120.
7. Mannucci PM, Citterio LE, Panajotopoulos N. Low-dose heparin and deep-vein thrombosis after total hip replacement. Thromb Haemost 1976;36:157-164.
8. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991;114:545-551.
9. Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med 1977;297:1246-1249.
10. Eriksson BI, Kälebo P, Anthymyr BA, et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg [Am] 1991;73-A:484-493.
11. Bauer KA, Eriksson BI, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310.
12. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement: enoxaparin Clinical Trial Group. J Bone Joint Surg [Am] 2001;83-A:336-345.
13. Haas SB, Insall JN, Scuderi GR, Windsor RE, Ghelman B. Pneumatic sequential-compression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. J Bone Joint Surg [Am] 1990;72:27-31.
14. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery - a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992;67:417-423.
15. McKenna R, Galante J, Bachmann F, et al. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J 1980;280:514-517.
16. Khan SK, Malviya A, Muller SD, et al. Reduced short-term complications and mortality following Enhanced Recovery primary hip and knee arthroplasty: results from 6,000 consecutive procedures. Acta Orthop 2014;85:26-31.
17. Lie SA, Pratt N, Ryan P, et al. Duration of the increase in early postoperative mortality after elective hip and knee replacement. J Bone Joint Surg [Am] 2010;92-A:58-63.
18. Poultsides LA, Gonzalez Della Valle A, Memtsoudis SG, et al. Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. J Bone Joint Surg [Br] 2012;94-B:113-121.
19. Cusick LA, Beverland DE. The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients. J Bone Joint Surg [Br] 2009;91-B:645-648.
20. Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg [Br] 2005;87-B:1675-1680.
21. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
22. Devereaux PJ, Xavier D, Pogue J, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med 2011;154:523-528.
23. No authors listed. National Joint Registry for England and Wales: 10th Annual Report, 2013. www.njrcentre.org.uk (date last accessed 17 April 2014).
24. Schousboe JT, Brown GA. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty. J Bone Joint Surg [Am] 2013;95-A:1256-1264.
25. Raskob GE, Gallus AS, Pineo GF, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg [Br] 2012;94-B:257-264.
26. Muller SD, Khaw FM, Morris R, Crozier AE, Gregg PJ. Ulceration of the lower leg after total knee replacement a five-year review. J Bone Joint Surg [Br] 2001;83-B:1116-1118.
27. Gould VC, Wylde V, Smith AJ, Blom AW. Patient-reported history of leg ulceration 12-16 years after total primary knee or hip replacement. Acta Orthop 2011;82:471-474.
28. Wang Z, Chen F, Ward M, Bhattacharyya T. Compliance with Surgical Care Improvement Project measures and hospital-associated infections following hip arthroplasty. J Bone Joint Surg [Am] 2012;94-A:1359-1366.
29. Jameson SS, Rymaszewska M, Hui AC, et al. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg [Am] 2012;94-A:1554-1558.
30. Jensen CD, Steval A, Partington PF, Reed MR, Muller SD. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg [Br] 2011;93-B:91-95.
31. Vanhegan IS, Malik AK, Jayakumar P, Ul Islam S, Haddad FS. A financial analysis of revision hip arthroplasty: the economic burden in relation to the national tariff. J Bone Joint Surg [Br] 2012;94-B:619-623.
32. Baker P, Petheram TG, Kurtz S, et al. Patient reported outcome measures after revision of the infected TKR: comparison of single versus two-stage revision. Knee Surg Sports Traumatol Arthrosc 2013;21:2713-2720.
33. No authors listed. Comparative effectiveness review summary guides for clinicians: venous thromboembolism prophylaxis in orthopedic surgery. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007.
34. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008;372:2152-2161.
35. Jameson SS, Charman SC, Gregg PJ, Reed MR, van der Meulen JH. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry. J Bone Joint Surg [Br] 2011;93-B:1465-1470.
36. Jameson SS, Baker PN, Charman SC, et al. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using National Joint Registry Data. J Bone Joint Surg [Br] 2012;94-B:914-918.
37. Bozic KJ, Vail TP, Pekow PS, et al. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty 2010;25:1053-1060.
38. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 2009;151:203-205.
39. No authors listed. Institute of Medicine: Initial National Priorities for Comparative Effectiveness Research. www.iom.edu/cerpriorities (date last accessed 31 October 2013).
40. Guyatt GH1, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):7S-47S.
41. No authors listed. American Academy of Orthopaedic Surgeons: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty: evidence-based guideline and evidence report. http://www.aaos.org/research/guidelines/VTE/VTE-full-guideline.pdf (date last accessed 17 April 2014).
42. Knesek D, Peterson TC, Markel DC. Thromboembolic prophylaxis in total joint arthroplasty. Thrombosis 2012;2012:837896.